Management of Infusion Reactions

Immediate Recognition and Grading

• For mild to moderate infusion reactions (Grade 1-2), the American Society of Clinical Oncology recommends immediately stopping or slowing the infusion rate and providing symptomatic treatment with antihistamines, with a strength of evidence based on clinical guidelines 1
• For severe reactions (Grade 3-4), the American Society of Clinical Oncology recommends stopping the infusion completely, administering epinephrine 0.3-0.5 mg intramuscularly for anaphylaxis, providing aggressive symptomatic treatment including corticosteroids, and permanently discontinuing the drug in most cases, with a high strength of evidence based on clinical trials 1

Acute Management by Severity

• For Grade 1-2 reactions, the European Society for Medical Oncology recommends stopping or slowing the infusion rate to 50-60 ml/h, administering symptomatic treatment with H1 antihistamines, and restarting the infusion at half the previous rate and titrating to tolerance, with a moderate strength of evidence based on clinical experience 1, 2
• For Grade 3 reactions, the American Society of Clinical Oncology recommends immediately stopping the infusion, providing aggressive symptomatic treatment including H1/H2 antihistamines and corticosteroids, and considering 24-hour observation, with a moderate strength of evidence based on clinical guidelines 1
• For Grade 4 reactions, the American Heart Association recommends permanently discontinuing the infusion, administering epinephrine 0.3-0.5 mg intramuscularly, and providing adjunctive medications, with a high strength of evidence based on clinical trials 1, 2

Drug-Specific Management Considerations

• For rituximab, the American Society of Clinical Oncology recommends premedicating with antipyretic and antihistamine, using a slow initial infusion rate, with a high strength of evidence based on clinical trials 1
• For cetuximab, the European Society for Medical Oncology recommends premedicating with corticosteroids plus antihistamines, with a moderate strength of evidence based on clinical experience 3
• For ofatumumab, the American Society of Clinical Oncology recommends premedicating with paracetamol, antihistamine, and IV corticosteroid, with a moderate strength of evidence based on clinical guidelines 2, 4

Rechallenge and Subsequent Infusions

• For Grade 1-2 reactions, the American Society of Clinical Oncology recommends implementing premedication with antipyretics and antihistamines for subsequent infusions, starting infusion at a slower rate, and gradually increasing infusion rate over subsequent treatments as tolerated, with a moderate strength of evidence based on clinical experience 1
• For Grade 3-4 reactions, the European Society for Medical Oncology recommends considering desensitization protocols, with a low strength of evidence based on clinical reports 1, 2

Management of Infusion Reactions

Immediate Recognition and Initial Response

• The American Society of Clinical Oncology recommends stopping the infusion immediately and assessing for anaphylaxis, administering epinephrine 0.2-0.5 mg intramuscularly if anaphylaxis is suspected, and providing symptomatic treatment with antihistamines and corticosteroids for milder reactions 5
• The European Society for Medical Oncology suggests evaluating ABCs (Airway, Breathing, Circulation) and level of consciousness, positioning the patient appropriately, administering supplemental oxygen if needed, and calling for medical assistance immediately 5

Determine Reaction Severity and Type

• The American College of Allergy, Asthma, and Immunology recommends immediate epinephrine administration for anaphylaxis, with a dose of 0.2-0.5 mg (1 mg/mL) intramuscularly into the lateral thigh muscle, and repeating every 5-15 minutes as needed 5
• The National Institute for Health and Care Excellence suggests using adjunctive medications for anaphylaxis, including H1/H2 antihistamines, corticosteroids, and atropine 600 μg IV if bradycardia develops 5

Drug-Specific Management Considerations

• The American Society of Clinical Oncology recommends premedication with corticosteroids plus antihistamines for cetuximab, and a slow infusion rate for the first dose 6
• The European Society for Medical Oncology suggests premedication with corticosteroids and H1/H2 antagonists for daratumumab, and no premedication for PD-1/PD-L1 inhibitors 6

Post-Reaction Management

• The American College of Emergency Physicians recommends monitoring vital signs continuously until complete resolution, and 24-hour observation after severe reactions 5
• The National Institute for Health and Care Excellence suggests recording specific symptoms, timing of onset, and treatments administered, and considering measuring tryptase levels 15 minutes to 3 hours after onset if anaphylaxis is suspected 5

Rechallenge Considerations

• The American Society of Clinical Oncology recommends against rechallenge in cases of anaphylaxis (Grade 4 reactions) and Grade 3/4 reactions with PD-1/PD-L1 inhibitors 5
• The European Society for Medical Oncology suggests considering desensitization protocols for platinum agents or taxanes with prior Grade 3/4 reactions 7

Common Pitfalls to Avoid

• The American College of Allergy, Asthma, and Immunology recommends never delaying epinephrine in suspected anaphylaxis, and not using corticosteroids alone without antihistamines in acute reactions 5
• The National Institute for Health and Care Excellence suggests avoiding first-generation antihistamines (diphenhydramine) in mild reactions, and not confusing drug-specific requirements 8

Premedication and Management of Mild Infusion Reactions

Recommended Premedication Regimen

• For patients who have experienced a Grade 1‑2 (mild to moderate) infusion reaction, administer methylprednisolone 40–125 mg IV (or an equivalent corticosteroid dose) 30–60 minutes before the next infusion to reduce the likelihood of recurrence. 9
• In the same population, give diphenhydramine 25–50 mg IV or orally 30–60 minutes prior to infusion as part of the premedication strategy. 9

Infusion Rate Adjustments

• Initiate the subsequent infusion at a reduced rate (approximately 50 % of the previously tolerated rate or 50–60 mL/h if the prior rate is unknown) because a slower initial infusion helps mitigate cytokine release even when premedication is used. 9

Management of Recurrent Reactions

• Grade 1‑2 reaction: If a mild reaction occurs during rechallenge, pause or slow the infusion to 50–60 mL/h, provide symptomatic treatment, wait at least 15 minutes after symptom resolution, then resume at 50 % of the original rate. 9
• Grade 3‑4 reaction: For severe reactions, discontinue the infusion permanently, administer intramuscular epinephrine (0.3–0.5 mg) if anaphylaxis is present, give aggressive additional corticosteroids and antihistamines, and consider a desensitization protocol for future dosing when the medication is essential. 9

Evidence Strength and Guideline Support

• The combined use of corticosteroids and antihistamines for premedication is endorsed by high‑quality oncology societies (e.g., ESMO 2017 and ASCO), with a moderate‑to‑high strength of evidence derived from clinical trials and extensive clinical experience, demonstrating a significant reduction in recurrent infusion reactions. 9